Price
CHART BY
Frequently asked questions
What is Moderna's market capitalization?
The market capitalization of Moderna is $15.16B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Moderna?
Moderna's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$5.825. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Moderna's stock?
Currently, 28 analysts cover Moderna's stock, with a consensus target price of $71.40. Analyst ratings provide insights into the stock's expected performance.
What is Moderna's revenue over the trailing twelve months?
Over the trailing twelve months, Moderna reported a revenue of $5.07B.
What is the EBITDA for Moderna?
Moderna's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$2.37B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Moderna?
Moderna has a free cash flow of -$3.96B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Moderna have, and what sector and industry does it belong to?
Moderna employs approximately 5,600 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Moderna's shares?
The free float of Moderna is 343.19M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $15.16B
- EPS (TTM)
- -$5.825
- Free Float
- 343.19M
- Revenue (TTM)
- $5.07B
- EBITDA (TTM)
- -$2.37B
- Free Cashflow (TTM)
- -$3.96B
Pricing
- 1D span
- $39.10$40.86
- 52W span
- $35.82$170.35
Analyst Ratings
The price target is $71.40 and the stock is covered by 28 analysts.
Buy
10
Hold
14
Sell
4
Information
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
- Employees
- 5,600
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US60770K1079
- Primary Ticker
- MRNA